Skip to main content
HairCited

Vitamine D pour Telogen Effluvium

F Effet La recherche montre que cette utilisation est peu susceptible d’être efficace.

Basé sur 32 études (1 meta-analysis, 1 RCT) avec 17,842 participants au total. Les résultats sont mitigés entre les études.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dvitamin\u002Dd\u0026condition\u003Dtelogen\u002Deffluvium'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

F

En conclusion

Despite frequent associations between low vitamin D and telogen effluvium, research does not clearly support vitamin D supplementation as an effective approach for this type of hair shedding.

  • Lower vitamin D levels are common in telogen effluvium patients but may not be the cause
  • No well-designed RCTs demonstrate that supplementation resolves telogen effluvium
  • Post-COVID hair loss studies show inconsistent findings regarding vitamin D
  • Correcting a deficiency is reasonable, but vitamin D alone is unlikely to resolve hair shedding

Key Study Findings

retrospective observational n=113
Telogen Effluvium Following Coronavirus Disease-2019 Infection: A Retrospective Study of 113 Cases.
Dose: None vs: Placebo Effet: None None
Meta-analysis
Vitamin D deficiency in non-scarring and scarring alopecias: a systematic review and meta-analysis.
Dose: None vs: Placebo Effet: OR=2.84 (AA vs controls), OR=5.24 (FPHL vs controls) p<0.01
meta_analysis n=10670
Serum 25 hydroxyvitamin D in non-scarring alopecia: A systematic review and meta-analysis.
Dose: not applicable (observational meta-analysis) vs: Placebo Effet: WMD -7.29 ng/mL (95% CI -9.21, -5.38); OR for vitamin D deficiency 3.11 (95% CI 2.29, 4.22) not explicitly stated; CI does

Key Statistics

34

Études

17842

Participants

Mixed

F

Note

Referenced Papers

Archives of dermatological … 2023 3 citations
Journal of dermatological … 2021 51 citations
Journal of cosmetic … 2021 44 citations
International journal of … 2020 18 citations
International journal of … 2017 61 citations
Skin pharmacology and … 2013 127 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
600-800 IU/day
deficiency:
1,000-5,000 IU/day

Limite supérieure : 4,000 IU/day

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Neutral 113
None -- Positive --
None -- Mixed --
None -- Negative --
not applicable -- Mixed 180
not applicable (observational meta-analysis) -- Negative 10670
None -- Mixed 100
None -- Neutral 120

Moment optimal de prise : With a fat-containing meal for optimal absorption

Safety & Side Effects

Effets indésirables signalés

  • Hypercalcemia at very high doses (nausea, vomiting, weakness)
  • Kidney stones with excessive long-term use
  • Constipation
  • Metallic taste

Interactions connues

  • Thiazide diuretics (may increase risk of hypercalcemia)
  • Corticosteroids (reduce vitamin D absorption and metabolism)
  • Orlistat and cholestyramine (reduce fat-soluble vitamin absorption)

Apport maximal tolérable : 4,000 IU/day

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Vitamine D help with Telogen Effluvium?
Based on 34 studies with 17,842 participants, there is insufficient evidence at this time that Vitamine D may support Telogen Effluvium management. Our evidence grade is F (Evidence Against).
How much Vitamine D should I take for Telogen Effluvium?
Studies have used various dosages. A commonly studied range is 600-800 IU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Vitamine D?
Reported side effects may include Hypercalcemia at very high doses (nausea, vomiting, weakness), Kidney stones with excessive long-term use, Constipation, Metallic taste. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Vitamine D and Telogen Effluvium?
We rate the evidence as Grade F (Evidence Against). This rating is based on 34 peer-reviewed studies with 17,842 total participants. The overall direction of effect is mixed.

References

  1. [1] Andrea Sechi et al.. Nutrients. 2025. Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients. doi:10.3390/nu17091451 PubMed
  2. [2] Namrata Chhabra et al.. Int J Trichology. 2025. Telogen Effluvium Following Coronavirus Disease-2019 Infection: A Retrospective Study of 113 Cases. doi:10.4103/ijt.ijt_38_22 PubMed
  3. [3] Adam Leavitt et al.. J Drugs Dermatol. 2025. Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. doi:10.36849/JDD.8763 PubMed
  4. [4] Irem Nur Durusu Turkoglu et al.. J Cosmet Dermatol. 2024. A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, vitamin B12, vitamin D, thyroid … doi:10.1111/jocd.16512 PubMed
  5. [5] Yuling Chen et al.. J Cosmet Dermatol. 2024. Serum 25 hydroxyvitamin D in non-scarring alopecia: A systematic review and meta-analysis. doi:10.1111/jocd.16093 PubMed
  6. [6] Nermeen Ibrahim Bedair et al.. Arch Dermatol Res. 2024. Post Covid telogen effluvium: the diagnostic value of serum ferritin biomarker and the preventive value of dietary supplements. a case … doi:10.1007/s00403-024-03004-1 PubMed
  7. [7] Tanat Yongpisarn et al.. Front Nutr. 2024. Vitamin D deficiency in non-scarring and scarring alopecias: a systematic review and meta-analysis. doi:10.3389/fnut.2024.1479337 PubMed
  8. [8] Palwasha Jalil et al.. Dermatol Pract Concept. 2024. Filling the Gaps: Vitamin D Status in Diffuse Hair Fall Among Pakistanis. doi:10.5826/dpc.1404a232 PubMed
  9. [9] Vivien Chen et al.. Pediatr Dermatol. 2023. Etiology, management, and outcomes of pediatric telogen effluvium: A single-center study in the United States. doi:10.1111/pde.15154 PubMed
  10. [10] Hakan Arslan et al.. Dermatol Pract Concept. 2023. Micronutrient Deficiencies and Digital Computerized Phototrichogram Analysis in Telogen Effluvium: a Retrospective Correlation Study in a Tertiary Medical Center. doi:10.5826/dpc.1303a202 PubMed
  11. [11] Marissa S Ceresnie et al.. Arch Dermatol Res. 2023. The development of non-scarring alopecia in women who wear the hijab. doi:10.1007/s00403-023-02713-3 PubMed
  12. [12] Rania Ahmed El-Tatawy et al.. Int J Trichology. 2023. Oral Vitamin D Treatment in Patients with Telogen Effluvium: Clinical and Dermoscopic Evaluation. doi:10.4103/ijt.ijt_92_22 PubMed
  13. [13] Ahu Yorulmaz et al.. J Cosmet Dermatol. 2022. Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium. doi:10.1111/jocd.14413 PubMed
  14. [14] Noor Altooq et al.. Hum Nutr Metab. 2022. The role of micronutrients in the management of COIVD-19 and optimizing vaccine efficacy. doi:10.1016/j.hnm.2022.200141 PubMed
  15. [15] Ümran Öner et al.. Turk J Med Sci. 2022. Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom? doi:10.3906/sag-2106-28 PubMed
  16. [16] Shawn Afvari et al.. J Am Acad Dermatol. 2022. Reply to "Vitamin D status in scarring and nonscarring alopecia". doi:10.1016/j.jaad.2022.04.055 PubMed
  17. [17] Saadet İbiş et al.. Dermatol Pract Concept. 2022. Evaluation of MCV/RDW Ratio and Correlations With Ferritin in Telogen Effluvium Patients. doi:10.5826/dpc.1203a151 PubMed
  18. [18] Elizabeth J Klein et al.. JAAD Int. 2022. Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. doi:10.1016/j.jdin.2022.08.013 PubMed
  19. [19] Ginny Oong Chien Yin et al.. J Dermatol Sci. 2021. Telogen Effluvium - a review of the science and current obstacles. doi:10.1016/j.jdermsci.2021.01.007 PubMed
  20. [20] Kriteeka Saini et al.. J Cosmet Dermatol. 2021. Role of vitamin D in hair loss: A short review. doi:10.1111/jocd.14421 PubMed
  21. [21] Khaled Babaei et al.. An Bras Dermatol. 2021. Characteristics of telogen effluvium in COVID-19 in western Iran (2020). doi:10.1016/j.abd.2021.05.006 PubMed
  22. [22] Zainab Zubair et al.. Cureus. 2021. Prevalence of Low Serum Vitamin D Levels in Patients Presenting With Androgenetic Alopecia: A Review. doi:10.7759/cureus.20431 PubMed
  23. [23] Farah Sattar et al.. J Nutr Sci Vitaminol (Tokyo). 2021. Efficacy of Oral Vitamin D3 Therapy in Patients Suffering from Diffuse Hair Loss (Telogen Effluvium). doi:10.3177/jnsv.67.68 PubMed
  24. [24] Diana Gruenstein et al.. Dermatol Online J. 2021. Telogen effluvium caused by COVID-19 in Elmhurst, New York: report of a cohort and review. doi:10.5070/D3271055619 PubMed
  25. [25] Sarita Sanke et al.. Int J Dermatol. 2020. Study of serum vitamin D levels in men with premature androgenetic alopecia. doi:10.1111/ijd.14982 PubMed
  26. [26] Ralf Paus et al.. Exp Dermatol. 2020. Topical L-thyroxine: The Cinderella among hormones waiting to dance on the floor of dermatological therapy? doi:10.1111/exd.14156 PubMed
  27. [27] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
  28. [28] Iman Seleit et al.. Clin Cosmet Investig Dermatol. 2019. Vitamin D Receptor Gene Polymorphism In Chronic Telogen Effluvium; A Case-Control Study. doi:10.2147/CCID.S227232 PubMed
  29. [29] Agnieszka Gerkowicz et al.. Int J Mol Sci. 2017. The Role of Vitamin D in Non-Scarring Alopecia. doi:10.3390/ijms18122653 PubMed
  30. [30] Evelyn J Cheung et al.. J Drugs Dermatol. 2016. Vitamin and Mineral Deficiencies in Patients With Telogen Effluvium: A Retrospective Cross-Sectional Study. PubMed
  31. [31] Tee Wei Siah et al.. Int J Trichology. 2016. Female Pattern Hair Loss: A Retrospective Study in a Tertiary Referral Center. doi:10.4103/0974-7753.188033 PubMed
  32. [32] Thamer Mubki. J Cutan Med Surg. 2014. Use of Vitamins and Minerals in the Treatment of Hair Loss: A Cross-Sectional Survey among Dermatologists in Saudi Arabia. doi:10.2310/7750.2014.14008 PubMed
  33. [33] H Rasheed et al.. Skin Pharmacol Physiol. 2013. Serum ferritin and vitamin d in female hair loss: do they play a role? doi:10.1159/000346698 PubMed
  34. [34] T O Bleiker et al.. Br J Dermatol. 2005. 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with … doi:10.1111/j.1365-2133.2005.06608.x PubMed

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.